Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial
Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. // The Lancet Regional Health - Western Pacific. – URL: https://www.sciencedirect.com/science/article/pii/S2666606526001999?dgcid=rss_sd_all
Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health - Western Pacific. https://www.sciencedirect.com/science/article/pii/S2666606526001999?dgcid=rss_sd_all
“Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial.” The Lancet Regional Health - Western Pacific.
@article{article69321,
title = {Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial},
journal = {The Lancet Regional Health - Western Pacific},
url = {https://www.sciencedirect.com/science/article/pii/S2666606526001999?dgcid=rss_sd_all}
}
ABSTRACT Aim To investigate the longitudinal association between early‐life movement behaviour patterns and later clinically diagnosed obesity. Method In the population‐based All Babies in Southeast Sweden (ABIS) cohort, 16 415 children...